Navigation Links
Poniard Pharmaceuticals Announces $6.5 Million Financing
Date:12/22/2009

hat are resistant to existing platinum-based cancer therapies. Clinical studies to date suggest that picoplatin has an improved safety profile relative to existing platinum-based cancer therapies. Poniard has completed a pivotal Phase 3 SPEAR (Study of Picoplatin Efficacy After Relapse) trial of picoplatin in the second-line treatment of patients with small cell lung cancer. The Company is also conducting separate Phase 2 trials evaluating picoplatin as a first-line treatment of metastatic colorectal cancer and castration-resistant (hormone-refractory) prostate cancer. Additionally, Poniard has completed a Phase 1 cardiac safety trial of picoplatin and a Phase 1 study evaluating the oral formulation of picoplatin in solid tumors. For additional information please visit http://www.poniard.com.

Forward-Looking Statement

This release contains forward-looking statements, including statements about the Company's financial condition and prospects, the sufficiency of current capital resources and the planned use of capital.. The Company's actual results may differ materially from those indicated in these forward-looking statements based on a number of factors, including risks and uncertainties inherent in the Company's business, including, but not limited to, the Company's anticipated operating losses and need for future capital; the risk that future financing alternatives may not be available on favorable terms or at all, the potential safety and efficacy of the Company's picoplatin product candidates; the receipt and timing of any FDA and other required regulatory approvals, if any; if regulatory approval of any product candidate is received, the market's acceptance of that product or the occurrence post-approval problems that ma
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
2. Poniard Pharmaceuticals Announces Upgrade of Stock Listing to NASDAQ Global Market
3. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
5. Poniard Pharmaceuticals Announces Upcoming Conference Participation
6. Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update
7. Poniard Pharmaceuticals Appoints Four New Members to Clinical Advisory Board
8. Poniard Pharmaceuticals to Host Second Quarter 2008 Financial Results Conference Call on July 31
9. Poniard Pharmaceuticals Announces Upcoming Conference Participation
10. Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center Translational Oncology Symposium
11. Poniard Pharmaceuticals Announces Upcoming Conference Participation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... Chicago, Illinois (PRWEB) October 30, 2014 ... Regenerative and Cellular Medicine Showcase in Chicago, leading ... and Orthopedic Surgeon, Dr. Wade McKenna presented talks ... Effectiveness and Orthopedic Surgical Applications For Stem Cells. ... of amniotic membrane and the properties of AlphaGEMS ...
(Date:10/30/2014)... 30, 2014 James Sherley says he has ... tissue stem cell technology since his days as a principal ... in the late 1990’s. Sherley founded the ASCTC as ... holds all the intellectual property developed in Sherley’s research over ... Massachusetts Institute of Technology (MIT), and more recently as a ...
(Date:10/30/2014)... Avure Technologies celebrates a year of success and the one-year ... of high volume High Pressure Processing (HPP) systems. , “We’re ... PackExpo this year, which is where we first announced the ... CEO at Avure. “Sales of the new Avure machine are ... challenges of market demand for higher throughput. We sold our ...
(Date:10/30/2014)... , Oct. 30, 2014 A new ... Technology Partnership Practice, takes an in-depth look at ... outputs that have resulted over two different time frames: ... provides a view of future opportunities for investment growth.  ... Indiana report shows gains in innovation dollars ...
Breaking Biology Technology:Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 2Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 3Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 4Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 2Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 3Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 4In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 2In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 3New report shows Indiana's gains in life sciences innovation capital outpace the nation 2New report shows Indiana's gains in life sciences innovation capital outpace the nation 3New report shows Indiana's gains in life sciences innovation capital outpace the nation 4New report shows Indiana's gains in life sciences innovation capital outpace the nation 5
... cause of death from roadside bombs to freeway crashes. Traumatic ... to 44, often overwhelms the body,s natural blood-clotting process. ... led by Erin Lavik, a new Case Western Reserve University ... Bertram, built synthetic platelets that show promise in halting internal ...
... Calif., Dec. 16 WaferGen Biosystems, Inc. (OTC Bulletin ... systems, today announced that it will be launching the ... profiling using its SmartChip(TM) Real-Time PCR System. The ... panel of 885 microRNAs on a single SmartChip. ...
... , LAS VEGAS, Dec. 16 Cord Blood America, Inc. (OTC ... ( http://www.cordblood-america.com ) focused on bringing the life saving potential ... internationally, said today that it has reduced its debt by a ... 2009 and total debt eliminated for the year now tops $10 ...
Cached Biology Technology:Researchers take the inside route to halt bleeding 2WaferGen to Launch Human MicroRNA Panel for Gene-Expression Profiling of 885 MicroRNA for Its Service Using the SmartChip(TM) Real-Time PCR System 2WaferGen to Launch Human MicroRNA Panel for Gene-Expression Profiling of 885 MicroRNA for Its Service Using the SmartChip(TM) Real-Time PCR System 3WaferGen to Launch Human MicroRNA Panel for Gene-Expression Profiling of 885 MicroRNA for Its Service Using the SmartChip(TM) Real-Time PCR System 4Cord Blood America Says 2009 Debt Reduction Tops $10 Million 2Cord Blood America Says 2009 Debt Reduction Tops $10 Million 3
(Date:10/30/2014)...  Securus Technologies, a leading provider of ... public safety, investigation, corrections and monitoring, announced ... to its THREADS™ product, which utilizes sophisticated ... and focused leads for investigators. ... through identifying and delivering solutions serving the ...
(Date:10/29/2014)... and gas production are well over recommended levels in ... journal Environmental Health . High levels of benzene, ... the first to be based on community sampling by ... used to supplement official air-quality monitoring programs. , Unconventional ... readily flow to the surface. This is because they ...
(Date:10/29/2014)... suffers who lose their hair as a consequence of ... will improve the scalp cooling technology that prevents hair ... is being pioneered by global scalp cooling manufacturing company, ... the biology department of the University of Huddersfield. , ... Hussain, who has a background in the pharmacology of ...
Breaking Biology News(10 mins):Securus Technologies Adds Advanced Features to Its Industry-Leading Investigative Analytics Product 2Air quality and unconventional oil and gas sites 2Air quality and unconventional oil and gas sites 3New technology on the way to aid cancer suffers who lose their hair after chemotherapy 2
... , A collaboration of French and Canadian researchers have found ... into a tiny pipette provides information about the adhesion between ... is a novel approach for the study of the structural ... as embryonic development, tissue growth and cancer. A paper describing ...
... 25 A two-year, $12 million contract with the ... will jumpstart human trials of three innovative research programs ... functional tissues, announced officials of the University of Pittsburgh ... the Institute,s Second Annual Open Session, Soldiers and Sailors ...
... Calif. More than a thousand microbial genomes have been ... years to better understand their roles in tasks ranging ... suggest roughly 10,000 microbial genomes will be publicly available ... not caught up with the technological advances that have ...
Cached Biology News:Pitt gets $12 million DoD contract for regenerative medicine treatment trials 2DOE JGI produces new QC tool for microbial genomes 2DOE JGI produces new QC tool for microbial genomes 3DOE JGI produces new QC tool for microbial genomes 4
MpV17 transgene, murine homolog, glomerulosclerosis...
Mouse monoclonal [6C3] to JAB1 ( Abpromise for all tested applications). entrezGeneID: 10987 SwissProtID: O15386...
Recombinant Ovine (Sheep) Prolactin, Ultra Pure...
Human LT beta R/TNFRSF3 Phycoerythrin MAb (Clone 71319)...
Biology Products: